← Leaderboards
Darcy V Spicer
University Of Southern California
$979,996
Attributed
$979,996
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$979,996 · 4
By mechanism
M01$538,398 · 2
S07$350,000 · 1
P30$91,598 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Sarah F Hamm-Alvarez$19,612,481
- Jeffrey S Weber$20,866,039
- Robert William Haile$42,901,503
- Cage S Johnson$1,950,654
- Ronald B Natale$275,537
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectNeoplasm /Cancer ChemotherapyHuman Therapy EvaluationPharmacokineticsCyclosporinesPaclitaxelDosageDrug Screening /EvaluationEnzyme InhibitorsFemaleFolatePurine /Pyrimidine MetabolismClinical Trial Phase IBreast NeoplasmsCombination Cancer TherapyHydroxymethyltransferasesWomen'S HealthPurinesHealth Care Service PlanningBiomedical FacilityData CollectionHealth AdministrationBehavioral /Social Science Research Tag
Grant awards (15)
SCCISARS 2: An e-Solution to Protect Human Subjects$350,000
S07 · FY2003 · RR
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2002 · RR
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER$0
M01 · FY2002 · RR
CORE--CLINICAL INVESTIGATIONS SUPPORT FACILITY$0
P30 · FY2002 · CA
CORE--CLINICAL INVESTIGATIONS SUPPORT FACILITY$0
P30 · FY2002 · CA
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER$155,764
M01 · FY2001 · RR
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER$155,764
M01 · FY2001 · RR
CORE--CLINICAL INVESTIGATIONS SUPPORT FACILITY$91,598
P30 · FY2001 · CA
CORE--CLINICAL INVESTIGATIONS SUPPORT FACILITY$0
P30 · FY2001 · CA
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2001 · RR
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER$0
M01 · FY2001 · RR
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER$155,764
M01 · FY2000 · RR
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER$35,553
M01 · FY2000 · RR
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER$35,553
M01 · FY2000 · RR
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER$0
M01 · FY2000 · RR